• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Sean E. Harper - Articles and news items

Amgen

Amgen presents long-term data showing efficacy and safety of investigational cholesterol-lowering medication evolocumab across lipid And LDL-C levels

Industry news / 19 November 2014 / Amgen

Additional data analysis showed every two week and monthly dosing regimens of evolocumab were clinically equivalent…

Amgen

Amgen joins The National Cancer Institute and Research Partners to help accelerate development of personalized treatment approaches for squamous cell lung cancer

Industry news / 17 June 2014 / Amgen

Amgen announced that it will collaborate with the National Cancer Institute (NCI), part of the National Institutes of Health, and other public and private sector partners on the Lung Master Protocol (Lung-MAP)…

Amgen

Brodalumab treatment improved clinical signs and symptoms in Phase 2 psoriatic arthritis study published in The New England Journal Of Medicine

Industry news / 12 June 2014 / Amgen

Phase 3 program underway to further assess Brodalumab as potential treatment for people living with psoriatic arthritis…

AstraZeneca

Amgen and AstraZeneca announce positive results from Phase III study of brodalumab (AMG 827) in patients with moderate-to-severe plaque psoriasis

Industry news / 12 May 2014 / AstraZeneca

Study evaluating novel investigational IL-17 receptor antibody meets all primary and secondary endpoints…

Amgen

Amgen provides update on Phase 3 study of talimogene laherparepvec in patients with metastatic melanoma

Industry news / 7 April 2014 / Amgen

Amgen announced top-line results from the primary overall survival analysis of a Phase 3 trial in melanoma, which evaluated the efficacy and safety of talimogene laherparepvec…

Amgen

Amgen announces positive top-line results from Phase 3 TESLA trial of evolocumab in patients with homozygous familial hypercholesterolemia

Industry news / 17 March 2014 / Amgen

Study meets primary endpoint of LDL cholesterol reduction First phase 3 data of a pcsk9 inhibitor in patients with homozygous familial hypercholesterolemia – a rare and serious disease…

Amgen

Amgen announces positive top-line results from Phase 3 RUTHERFORD-2 trial of evolocumab in patients with heterozygous familial hypercholesterolemia

Industry news / 30 January 2014 / Amgen

RUTHERFORD-2 study meets co-primary endpoints of ldl cholesterol reduction Amgen also announces results from phase 3 study with automated mini-doser completion of fifth phase 3 study forms basis for global filing plan…

Amgen

Amgen announces positive top-line results from Phase 3 LAPLACE-2 trial of Evolocumab (AMG 145) in combination with statins in patients with high cholesterol

Industry news / 28 January 2014 / Amgen

Amgen announced that the Phase 3 LAPLACE-2 trial evaluating evolocumab in combination with statin therapy in patients with high cholesterol met its co-primary endpoints…

Amgen logo
Amgen logo

Romosozumab Phase 2 data published In New England Journal Of Medicine show significant increases in bone mineral density at both spine and hip

Industry news / 1 January 2014 / Amgen

“The results of the study demonstrate significantly increased BMD and stimulation of bone formation with romosozumab treatment…”

Amgen logo
Amgen logo

Amgen announces evolocumab (AMG 145) results from first 52-week study of a PCSK9 inhibitor to reduce LDL cholesterol

Industry news / 20 November 2013 / Amgen

Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation…

 

Webinar: Use of MicroNIR to optimise fluid bed drying and to reduce waste at tablet compressionFIND OUT MORE
+ +